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Abstract
Background: The Eosinophil Cationic Protein (ECP) is a potent multifunctional protein. Three common
polymorphisms are present in the ECP gene, which determine the function and production of the protein. The aim
was to study the relationship of these ECP gene polymorphisms to signs and symptoms of allergy and asthma in a
community based cohort (The European Community Respiratory Health Survey (ECRHS)).
Methods: Swedish and Estonian subjects (n = 757) were selected from the larger cohort of the ECRHS II study
cohort. The prevalence of the gene polymorphisms ECP434(G>C) (rs2073342), ECP562(G>C) (rs2233860) and ECP
c.-38(A>C) (rs2233859) were analysed by DNA sequencing and/or real-time PCR and related to questionnaire-based
information of allergy, asthma, smoking habits and to lung functions.
Results: Genotype prevalence showed both ethnic and gender differences. Close associations were found between
the ECP434(G>C) and ECP562(G>C) genotypes and smoking habits, lung function and expression of allergic
symptoms. Non-allergic asthma was associated with an increased prevalence of the ECP434GG genotype. The ECP
c.-38(A>C) genotypes were independently associated to the subject being atopic.
Conclusion: Our results show associations of symptoms of allergy and asthma to ECP-genotypes, but also to
smoking habits. ECP may be involved in impairment of lung functions in disease. Gender, ethnicity and smoking
habits are major confounders in the evaluations of genetic associations to allergy and asthma.
Background
The Eosinophil Cationic Protein (ECP), also named
RNase 3, is a multifunctional protein with both cyto-
toxic and fibrogenic properties [1-3]. High levels of ECP
were found in blood, bronchoalveolar lavage, saliva and
sputum of subjects with allergic asthma indicating the
presence of activated eosinophils in the disease process
[1,4]. Recently several common polymorphisms were
described in the ECP gene [5]. One of these polymorph-
isms ECP434(G>C) affects the protein coding part of
ECP and gives rise to a change in the amino acid argi-
nine at position 97 to threonine [2]. This substitution
dramatically alters the function of ECP from a cytotoxic
to a non-cytotoxic molecule. Another polymorphism
was found in the 3’UTR region ECP562(G>C) and
shown to be related to the cellular content of ECP [6].
A third polymorphism was seen in the intron of the
ECP gene, ECP c.-38(A>C), and shown by others to be
related to serum levels of ECP [7]. We found previously
a close relationship between the ECP434(G>C) poly-
morphism and the expression of allergic symptoms such
as asthma [8] whereas another group showed associa-
tions between the ECP c.-38(A>C) polymorphism and
various symptoms of allergy and asthma and a relation
to non-allergic asthma of the ECP434(G>C) polymorph-
ism [7]. In an unpublished pilot study we found lower
lung function, as measured with FEV1,i ns m o k e r sw h o
carried the ECP434GG genotype.
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possible relationships between the three common ECP
gene polymorphisms to allergy/asthma and lung func-
tion. For this purpose we have genotyped a sub cohort
of the European Community Respiratory Health Survey
II (ECRHS II) study cohort [9] and related the genotypes
to questionnaire-based information of allergy, asthma
and smoke habits as well as to various measures of lung
function.
Methods
Subjects
The European Community Respiratory Health Survey
(ECRHS) is an international multi-centre study of
asthma and allergy. The first part, ECRHS I, was con-
ducted in 1990-1994 and the follow-up study, ECRHS
II, in 1999-2001. The design of ECRHS I and ECRHS II
has been published in detail [9,10]. Each participant was
sent a brief questionnaire (Stage 1) and from those who
responded, a random sample was invited to undergo a
more detailed clinical examination (Stage 2). In addition
a “symptomatic sample” consisting of those who
reported symptoms of wakening with shortness of
breath, asthma attacks or using asthma medication in
stage 1 was also studied. In ECRHS II subjects who had
participated in stage 2 of ECRHS I were invited to parti-
cipate in a follow-up study. Subjects answered a standar-
dised questionnaire administered by trained interviewers
and underwent lung function test and blood test. Stage
2 of ECRHS I included 1382 subjects from Uppsala in
Sweden and Tartu in Estonia. Of these, 1054 subjects
were from the random sample and 328 from the symp-
tomatic sample. The ECRHS II in Uppsala and Tartu
included 1007 subjects of which DNA was available
from 757 subjects. Of these 757 subjects 574 were from
the randomly selected sample and 183 from the ‘symp-
tomatic sample’. The demographics of the randomly
selected cohort is shown in Table 1 and further
described below. The study was approved by the
local ethics committees of Tartu, Estonia and Uppsala,
Sweden. All subjects included in the study gave their
informed consent to participate.
Respiratory symptoms and asthma
The subjects underwent a structured interview, which
included detailed information on respiratory symptoms
and asthma. The symptoms included in this analysis had
all occurred during the preceding 12 months and were:
wheeze; wheeze in combination with breathlessness;
wheeze when not having a cold, nocturnal chest tight-
ness; attacks of breathlessness following activity, at rest
or at night time; and nocturnal cough. “Asthma” was
defined as having physician-diagnosed asthma and hav-
ing had asthma-related symptoms or attacks of asthma
in the preceding 12 months [11].
Allergy testing
Total and specific serum IgE was determined using the
Pharmacia CAP System (Phadia AB, Uppsala, Sweden).
Specific IgE was measured against Dermatophagoides
pteronyssinus, timothy grass, cat and Cladosporium her-
barum. Detection of specific IgE (≥ 0.35 kU/L) was used
as the definition of sensitisation. Atopy was defined as
being sensitised to any of the above allergens. In this
analysis allergic asthma was defined as having asthma in
combination with atopy, while non-allergic asthma was
defined as having asthma but not having atopy [12].
Smoking history
Information on smoking history was retrieved from the
main questionnaire [13]. Those who answered “yes” to
the lead question (“Have you ever smoked for as long as
a year?”) were classified in ex-smokers and current smo-
kers based on a negative/positive answer to the question
regarding the current consumption (“Do you now
smoke, as for one month ago?”).
Table 1 Differences and similarities in the randomly selected cohorts of Sweden and Estonia
Sweden Estonia All p-value (c
2-test)
Men/Women 185/169 (52%/48%) 96/130 (42%/58%) 281/299 (48%/52%) 0.021
Never-smokers/Ex-smokers/Smokers 171/124/53 (49%/36%/15%) 107/30/89 (47%/13%/39%) 278/154/142 (48%/27%/25%) < 0.0001
Atopy, no/yes 244/104 (70%/30%) 176/47 (79%/21%) 420/151 (74%/26%) 0.020
Asthma, no/yes 318/29 (92%/8%) 221/5 (98%/2%) 539/34 (94%/6%) 0.002
ECP434(G>C)
GG/GC/CC
190/146/13 (54%/42%/4%) 147/73/5 (65%/32%/2%) 337/219/18 (59%/38%/3%) 0.030
ECP562(G>C)
GG/GC/CC
231/110/7 (66%/32%/2%) 169/53/3 (75%/24%/1%) 400/163/10 (70%/28%/2%) Ns
ECP c.-38(A>C)
AA/AC/CC
77/182/89 (22%/52%/26%) 39/115/71 (17%/51%/32%) 116/297/160 (20%/52%/28%) Ns
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Forced expiratory volume in one second (FEV1)w a s
measured. Up to five technically acceptable blows were
determined. The ATS recommendations were followed
[14]. The predicted values for FEV1 were calculated on
the basis of the European Coal and Steel Union refer-
ence values [15].
DNA extraction
Genomic DNA was extracted from EDTA-containing
whole blood samples collected from 465 individuals of
the Swedish population and 292 individuals of the
Estonian population. The protocol from the manufac-
turer of the automated BioRobot M48 System (Geno-
vision, Qiagen GmbH, Hilden, Germany), designed for
the MagAttract® DNA Blood Mini M48 Kit (Qiagen),
based on magnetic-bead technology was used. DNA
from 200 μL of blood was eluted in an equal volume
of elution buffer. A limited number of reference sam-
ples used for DNA sequencing were extracted by a
method previously described by Kawasaki with minor
modifications [8,16].
Genotyping
Three single nucleotide polymorphisms (SNPs) in the
ECP gene, ECP c.-38(A>C) rs2233859, ECP434(G>C)
rs2073342, and ECP562(G>C) rs2233860 were genotyped
by the TaqMan 5’ nuclease allelic discrimination assay
(Applied Biosystems, Foster City, CA, USA), as previously
described [17,18]. Primers and probes (Table 2) were
designed according to the guidelines of the manufacturer.
Each PCR (polymerase chain reaction) contained tem-
plate DNA, TaqMan® Universal PCR Master Mix or Taq-
Man® Genotyping Master Mix (Applied Biosystems),
minor grove binding (MGB) probes (200 nmol/L and pri-
mers (700 or 900 nmol/L) (Applied Biosystems) and
non-acetylated bovine serum (100 or 200 μg/mL)
(Sigma-Aldrich, St. Louis, MO, USA). The PCR amplifi-
cation was run according to the standard protocol con-
sisting of 50°C for 2 min, 95°C for 10 min, and 40 cycles
of 95°C for 15 s, followed by 60°C for 1 min. The geno-
type was determined by use of the application Allelic Dis-
crimination of the ABI PRISM 7000 SDS software. Each
run included three non-template controls and two posi-
tive controls of each genotype previously analysed by the
use of PCR and restriction fragment length polymorph-
ism analysis (RFLP) in case of ECP434(G>C) or sequen-
cing as previously described in case of ECP434(G>C),
ECP562(G>C) and ECP c.-38(A>C) [6,8]. Samples geno-
typed as ECP562CC by the TaqMan® method described
above (Method 1) were re-genotyped after amplification
of a 870 base pair (bp) fragment of the ECP gene by PCR,
followed by the TaqMan 5’nuclease Allelic Discrimina-
tion assay (Method 2, Table 2).
C) polymorphism",1,0,1,0,0pc,0pc,0pc,0pc>DNA
Sequencing of the ECP c.-38 (A>C) polymorphism
A 710 bp fragment of the ECP gene was amplified in a
50 μL PCR reaction containing,t e m p l a t eD N A ,P l a t i -
num® Taq DNA Polymerase (1.0 unit), PCR buffer, 2’-
deoxynucleoside 5’-triphosphate (dNTP mixture) (0.05
mmol/L), MgCl2 (1.5 mmol/L) (Invitrogen, Carlsbad,
CA, USA), non-acetylated bovine serum (160 μg/mL)
(Sigma-Aldrich) and primers (0.2 μmol/L) (Thermo
Electron GmbH, Ulm, Germany) (Table 2). The PCR
reactions were run on a Thermo Cycler SDS instrument
(MJ Research, Inc., Waltham, MA, USA) with the fol-
lowing PCR profile: 94°C for 30 s, followed by 30 cycles
Table 2 ECP primers and probes derived from the gene sequence of GenBank accession number X16545
Polymorphism Primer Probe
a
ECP c.-38(A>C)
bFP: 5’-ATA GTT TTC ACC CAG AGT CCA-3’
(rs2233859)
bRP: 5’-TGC CCG CAT TGC AAT GGT GCA TCG A-3’
cFP: 5’-CAC CCA GAG TCC AGA TCC CAC CG-3’
cRP: 5’-GCA TTG CAA TGG TGC ATC GAG-3’
ECP c.-38(A>C) FP: 5’-GCC TGT GGG TTG AGA CAC TAT AGA-3’ C: 5’-VIC-AGT AAC TAC TCC CCg ATC C-3’
RP: 5’-ATT TGG GAA GTG AAC AGT TTT GG-3’ A: 5’-6-FAM-AGT AAC TAC TCC CCt ATC C-3’
ECP434(G>C) FP: 5’-GAG TAG ATT CCG GGT GCC TTT ACT-3’ G: 5’-VIC-AAA CTG CAg GTA TGC AGA-3’
(rs2073342) RP: 5’-CGT GGA GAA TCC CGT GGA T-3’ C: 5’-6-FAM-AAA CTG CAc GTA TGC AG-3’
ECP562(G>C)
d FP: 5’-GGT TCC AGT TCA CCT GGA TAC C-3’ G: 5’-VIC-TCA GCA gTC CTC ATC-3’
(rs2233860) RP: 5’-GGT ATG GAG ACT GAT GAG GAC AGT-3’ C: 5’-6-FAM-TCA GCA cTC CTC ATC-3’
ECP562(G>C)
ef FP: 5’-AAA TGC GAC CCC AGA GTG GCA-3’
fRP: 5’-AGG GGG AGA GAT TCA TGA TAA ACC C-3’
FP: 5’-GGT TCC AGT TCA CCT GGA TAC C-3’ G: 5’-VIC-TCA GCA gTC CTC ATC-3’
RP: 5’-TGA TTG AGG AGC TTG GCA GAT-3’ C: 5’-6-FAM-TCA GCA cTC CTC ATC-3’
FP: forward primer; RP: reverse primer, a: Polymorphic bases are indicated by lower cases, b: PCR primers, c: sequencing primers, d: Method 1, e: Method2 ,
f: amplification of a fragment of the ECP gene
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terminated by an additional extension for 5 min at 72°C.
The PCR products were analysed by agarose gel (1%)
electrophoresis, and purified by the QIAquick® PCR Pur-
ification Kit (Qiagen). The sequencing PCR was set up
with the GenomeLab™ Dye Terminator Cycle Sequen-
cing (DTCS) Quick Start Kit (Beckman Coulter, Inc.,
Fullerton, CA, USA), and subjected to Thermal Cycling
in the SDS instrument according to the protocol of the
manufacturer. The PCR products were ethanol precipi-
tated, dissolved in Sample Loading Solution (SLS), and
loaded into the CEQ™ 8000 DNA analysis system. Sub-
sequently, the nucleic acid sequences were analysed
using the software Vector NTI Advance™ 9.0 Software
package (InforMax, North Bethesda, MD, USA).
Statistics
In the comparison of mean and/or median levels of
more than two groups we used both parametric
ANOVA and the non-parametric Kruskal-Wallis test. In
the calculation of differences between two groups either
t-test or Mann Whitney’s non-parametric test were
used. In the calculations of differences in proportions
the c
2-test or Fisher’s exact test were used. In our calcu-
lations we made no assumptions as to the inheritance
patterns of the alleles. Logistic and multiple regression
analyses were performed to study interactions and adjust
for confounders. In the models gender, ethnicity, smok-
ing habits were included as categorical data together
with the three genotypes. In this way association to
atopy, asthma-like symptoms and smoking habits were
examined as dependent variables in forward and back-
ward analyses. In our calculations only the randomly
selected population of subjects was included unless
otherwise stated. In all calculations the statistical soft-
wares Statistica for Windows v. 9 (Tulsa, OK, USA) or
Medcalc v. 9 (Mariakerk, Belgium) were used.
Results
Demographics
Some of the differences and similarities between the two
cohorts from Sweden and Estonia are given in table 1.
This shows that more women and smokers were
included in the Estonian cohort. More subjects with
atopy were included in the Swedish cohort. The overall
prevalence of atopy was 27%, with 30% in the Swedish
cohort and 21% in the Estonian cohort, p = 0.02. A dif-
f e r e n c ew a ss e e ni nt h ep r e v a l e n c eo fa s t h m as i n c e2 %
of the Estonian cohort was diagnosed with asthma as
compared to 8% in the Swedish cohort (p = 0.002). We
found significant differences in genotype and allele fre-
quencies between the Swedish and Estonian cohorts
with the ECP434GG genotype and ECP434 G-allele
more common among Estonians (p = 0.030 and p =
0.017, respectively), but with no differences in ECP562
(G>C) or ECP c.-38(A>C) genotype frequencies.
Atopy and smoking habits were similar between gen-
d e r s ,w h e r e a st h ep r e v a l e n c eo fa s t h m aw a ss l i g h t l y
higher among women (p = 0.05) (Table 3). The preva-
lences of the ECP434 and ECP562 G-alleles were signifi-
cantly higher among women (p = 0.004 and 0.018,
respectively), whereas no gender differences were seen
for the ECP c.-38(A>C) gene polymorphism.
Relationships of ECP genotypes to smoking and lung
functions
Overall current smokers had a higher prevalence of the
ECP434 and ECP562 G-alleles than the non-smoking
cohort (p = 0.007 and 0.018, respectively). When sepa-
rated into never smokers, ex-smokers and current smo-
kers, ex-smokers had the lowest prevalence of the
ECP434 or ECP562 G-alleles (p = 0.001 and p = 0.0001,
respectively), with no differences between never smokers
and current smokers (Table 4). Smoking women had a
significantly higher prevalence of the ECP434 and
ECP562 G-alleles than smoking men (91% vs 77% and
94% vs 84%, p = 0.002 and p = 0.02, respectively).
Lung function as measured by FEV1 predicted was
similar among the ECP genotypes. However, among
women a significant relationship was found with higher
FEV1 predicted in those carrying the ECP434CC
genotype as compared to ECP434GC (p = 0.01) and as
compared to ECP434GG (p = 0.03) (Figure 1). This rela-
tionship was only seen among non-smoking women
Table 3 Differences and similarities between males and females in the randomly collected cohort
Male Female All p-value (c
2-test)
Never-smokers/Ex-smokers/Smokers 121/79/76 (44%/29%/28%) 157/75/66 (53%/25%/22%) 278/154/142 (47%/27%/26%) Ns
Atopy, no/yes 193/82 (70%/30%) 227/69 (77%/23%) 420/151 (74%/26%) Ns
Asthma, no/yes 267/11 (96%/4%) 272/23 (92%/8%) 539/34 (94%/6%) 0.05
ECP434(G>C)
GG/GC/CC
143/127/9 (51%/46%/3%) 194/92/9 (65%/32%/3%) 337/219/18 (59%/38%/3%) 0.002
ECP562(G>C)
GG/GC/CC
175/101/2 (63%/36%/1%) 225/65/8 (76%/21%/3%) 400/163/10 (70%/28%/2%) 0.0002
ECP c.-38(A>C)
AA/AC/CC
48/152/79 (17%/54%/28%) 68/145/81 (23%/49%/28%) 116/297/81 (20%/52%/28%) Ns
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ECP562(G>C) genotype, but not to the ECP c.-38(A>C)
genotype.
Relationships of ECP genotypes to atopy and asthma
Among males, but not among women, atopy was asso-
ciated to the ECP c.-38(A>C) genotypes with signifi-
cantly higher frequency of the CC-genotype (p = 0.007).
In a logistic regression analysis the ECP c.-38CC geno-
type was independently associated with an increased risk
of atopy in the randomly selected group (OR 1.9, CI 1.2-
3.1, p = 0.007) when adjusted for gender, ethnicity and
smoking habits. In order to evaluate any associations to
asthma and asthma-like symptoms the whole cohort of
subjects was included in the calculations, since the num-
ber of subjects with asthma in the randomly selected
group was very limited. We did not find any relation-
ships between asthma and genotypes in the entire
cohort. By logistic regression analysis with adjustment
for gender, ethnicity and smoking habits we confirmed
the apparent absence of any associations. However, in
the non-smoking cohort the ECP434GG genotype was
significantly more common in subjects with non-allergic
asthma (p = 0.016). This is illustrated in table 5 by the
non-smoking Swedish cohort in which 83% of the non-
allergic asthmatics carried the ECP434GG genotype as
compared to 48% of the subjects with allergic asthma
(p = 0.01). Non-allergic asthma was significantly more
prevalent among women (women 46% vs men 16%) and
allergic asthma more prevalent among men (women
54% vs men 84%) (p = 0.002). Subjects with non-allergic
asthma, in contrast to subjects with allergic asthma,
more frequently carried the ECP434GG genotype as
compared to non-asthmatics (83% vs 51%, p = 0.006).
A higher frequency of the ECP434GG genotype was
found among the non-smoking subjects who experi-
enced asthma-like symptoms at exposure to house dust
(p = 0.04) or to pollen (p = 0.03). Associations to these
symptoms (p < 0.05 and p = 0.007, respectively) are illu-
strated in table 5 for the non-smoking Swedish popula-
tion. Any associations were not seen to the ECP562
(G>C) and ECP c.-38(A>C) genotypes.
Discussion
In previous studies we showed a relation between the
ECP gene polymorphism 434(G>C) and the expression
of allergic symptoms [8]. The aim of this study was to
confirm and extend this observation in a larger cohort.
Three major confounders were identified that interfered
with the interpretation of our data. One was the
Table 4 The prevalence of the three ECP genotypes in the never-smoking, ex-smoking and smoking random cohorts
of Sweden and Estonia
Never-smokers Ex-smokers Smokers p-value (c
2-test)
ECP434(G>C)
GG/GC/CC
170/97/9 (62%/35%/3%) 65/80/7 (43%/53%/5%) 96/42/2 (69%/30%/1%) 0.0001
ECP562(G>C)
GG/GC/CC
197/73/6 (71%/26%/2%) 88/60/3 (58%/40%/2%) 109/30/1 (78%/21%/1%) 0.0048
ECP c.-38(A>C)
AA/AC/CC
59/142/75 (21%/51%/27%) 22/85/44 (15%/56%/29%) 33/66/41 (24%/47%/29) Ns
Swedish smoking men
1.04
1.06
1.08
1.10
p=0.04
All women
1.22
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1.26
1.28
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Figure 1 Lung function (FEV1 predicted) in relation to ECP434(G>C) genotypes. The relation is shown for two cohorts: All women (left
panel) and Swedish smoking men (right panel). The statistics is shown in the figure.
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ish cohorts, the other a gender difference and third and
most unexpectedly a close relationship between smoking
habits and the ECP434(G>C) genotypes. Thus, in the
Estonian cohort the C-allele was under represented as
compared to the Swedish population and also as com-
pared to previous population studies in Sweden. Like-
wise was the C-allele under represented among women.
A similar gender relationship was also seen for the
ECP562(G>C) polymorphism, which is expected based
on the previous findings of very close relationships
between these two genotypes with an r
2 of 0.64 (p <
0.001) [6]. However, the ECP c.-38(A>C) polymorphism
did not show such differences. Overall the genotype fre-
quencies of the ECP562(G>C) and ECP c.-38(A>C) were
consistent with Hardy-Weinberg equilibrium, whereas
the ECP434(G>C) genotype frequencies were consistent
with Hardy-Weinberg equilibrium in the Estonian
cohort, but not in the Swedish cohort (c
2 =6 . 2 ,p=
0.01).
The findings of strong associations between smoking
habits and the ECP434(G>C) and 562(G>C) genotypes
were unexpected and not easily explained. It is impor-
tant to emphasize that the relations to smoking habits
were seen in both ethnic groups, which makes the asso-
ciation more likely. Genetic relations to smoking habits,
however, have been documented extensively by others
and include relations to nicotine receptor polymorph-
isms, the dopamine and serotonin systems [19,20]. In a
recent genome wide association study candidate genes
for successful smoke cessation was performed and
showed candidate genes spread over the entire genome,
but within certain clusters [21]. Several candidate genes
were found on chromosome 14, which is the location of
the ECP gene. Three of these are located up streams the
ECP gene with distances from the ECP gene between
108 and 143 kbp. One of these is the RNASE6 gene.
However, a HapMap survey of a 500 kbp region around
the ECP gene revealed no linkages of interest apart from
the known linkage to the EPX/EDN gene (to be pub-
lished Jönsson et al.) and to the ECP pseudogene and
several intergene SNPs.
In an unpublished study we previously found a rela-
tionship between lung function and the ECP434(G>C)
genotype in women, since women who carried the GG
genotype had significantly reduced lung function as
measured by FEV1. Based on these findings we
hypothesized that ECP is involved in the impairment
of lung function and that those who express the non-
cytotoxic variant of ECP are protected from the conse-
quences of the detrimental effects of invading eosino-
phils in diseases such as seen in smokers, asthma and
COPD. Our findings in the present study also showed
a relationship between lung function and the genotypes
of ECP434(G>C) and ECP562(G>C), since women who
carried the CC genotypes had significantly higher FEV1
predicted. This association was found irrespective of
smoking habits, but was significant only among non-
smoking women. The numbers, however, of ever
smoking women carrying the CC genotypes were very
few, which precluded any further calculations. Thus,
our previous hypothesis had some support from these
findings. The need of further studies to validate our
findings is obvious.
We confirmed previous results of a relationship
between expression of allergic symptoms and the
ECP434(G>C) genotypes, [8] since self reported com-
plaints of allergic symptoms in contact with pollen and
house dust were more frequent among those who car-
ried the ECP434GG genotype. Also none of the subjects
in the randomly selected group of subjects who reported
symptoms of asthma carried the ECP434CC genotype.
One paradox, however, was that non-allergic asthma
was closely related to this genotype as well, in contrast
to allergic asthma, since non-allergic asthma primarily
was seen in women who carried the ECP434GG geno-
type. This is obviously contradicting our previous find-
ings in which we found a higher prevalence of the
ECP434GG genotype among allergic asthmatics [8]. In
the previous study the distinctions were based on doc-
tor’s diagnosis of asthma, whereas the distinction in this
survey was based on questionnaires and the retrospec-
tive diagnosis of the investigators. Moreover, our study
included both randomly selected subjects with asthma
Table 5 The associations of the ECP434(G>C) gene polymorphism to symptoms and signs of asthma and allergy in the
non-smoking Swedish population (random and symptomatic sample)
434GG 434GC 434CC p-value (c
2-test)
Asthma Yes
No
46 (58%)
155 (51%)
30 (38%)
129 (43%)
3 (4%)
15 (5%)
Ns
Allergic Asthma Yes
No
27 (48%)
19 (83%)
27 (48%)
3 (13%)
2 (4%)
1 (4%)
p = 0.01
Asthma-like symptoms to house dust Yes
No
19 (73%)
183(54%)
5 (20%)
157(42%)
2 (7%)
16 (4%)
p < 0.05
Asthma-like symptoms to pollen Yes
No
38 (63%)
163 (51%)
16 (27%)
146 (45%)
6 (10%)
12 (4%)
p = 0.007
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history of asthma, which may have biased our results
slightly. Whether this explains the seeming paradox is
unknown at present, but another study on Norwegian
and Dutch subjects with asthma found a relation of this
genotype to non-allergic asthma [7]. Further studies are
needed to settle this matter. A confounder in the pre-
sent study was the high prevalence of the ECP434GG
genotype in women, which paralleled the predominance
of non-allergic asthma among women.
In the above mentioned study on Norwegian and
Dutch subjects relationships between the ECP c.-38
(A>C) genotypes and signs of asthma and serum IgE
levels were found in addition to a relationship to
serum ECP levels [7]. We also found associations to
atopy, but our findings were opposite since atopy was
more prevalent in subjects carrying the ECP c.-38CC
genotype, whereas the A-allele seemed more prevalent
in the Norwegian-Dutch study. Our findings showed
by logistic regression analysis that this association was
independent when adjusted for the major confounders;
gender, ethnicity and smoking habits. However, in
separate evaluations of sub groups the association to
atopy were only seen in the Swedish cohort and most
obvious among non-smokers and males. In contrast to
the two ECP gene polymorphisms 434(G>C) and c.-38
(A>C) we found very few associations to the third
gene polymorphism i.e. ECP562(G>C). This confirms
our previous study and shows that the cellular content
of ECP is not a major determinant of disease develop-
ment, [6] whereas the quality in terms of cytotoxic
activity of the protein seems more important. Theore-
tically, the combination of the genotypes should give
us stronger disease associations. However, this was not
t h ec a s e( r e s u l t sn o ts h o w n ) ,s i n c et h es t r o n g e s tr e l a -
tionships were found with single genotype polymorph-
isms and not haplotypes of the three genotypes. In this
report we did not correct statistically for multiple
comparisons, which may limit our conclusions. How-
ever, the fact that we saw relationships to several aller-
gic manifestations would support our notions of the
impact of the ECP genotypes.
Conclusion
We conclude from this study that the three common
ECP genotypes are related to several signs and symp-
toms of allergy and asthma, but that confounders such
as gender, ethnicity and smoking habits have to be con-
sidered in the evaluations. The most conspicuous results
were the strong relationships to smoking habits and
lung function of the ECP434(G>C) genotypes, which
suggests that the activity of ECP may be of importance
for the development of irreversible damage to the lung
in smokers and pulmonary diseases. Indeed ECP is
highly cytotoxic and able to destroy lung epithelial cells,
[1,22] but may also take part in the remodelling of the
lungs seen in smokers [23].
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